Clinical trial · Observational
Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy
Retrospective Validation for Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy With S-1
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Adjuvant chemotherapy followed by curative gastrectomy for Stage II/III gastric cancer has improved disease free time and survival. However, there are still considerable number of patients experience relapse even after adjuvant chemotherapy. In an attempt to select patients who really benefit the postoperative adjuvant chemotherapy, we have identified potential biomarkers (NF-kappaB/JNK) from cell line panel screening followed by immunohistochemical validation. In the present study, we further validate the significance of the biomarkers in a larger set of clinical samples to see if chemotherapeutic response can be determined immediately after surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Biomarker positive
- description
- NF-kB(+)/JNK(-) in curatively removed specimens
- label
- Biomarker negative
- description
- NF-kB(-)/JNK(+) in curatively removed specimens
Primary outcomes (1)
- measure
- Relapse free survival
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed gastric cancer. * Operated before November 2009. * Stage Ib/II(except for T1, T3N0)/III. * Received postoperative (R0) adjuvant chemotherapy (S-1). * Not received postoperative (R0) adjuvant chemotherapy (surgery alone). * Signed informed consent to provide paraffin embedded tissue of removed specimens. Exclusion Criteria: * With advanced neoplastic lesions other than gastric cancer. * Paraffin embedded tissue is not available. * Unknown S-1 treatment condition.
References
Publications (1)
- BACKGROUNDIshida K, Nishizuka SS, Chiba T, Ikeda M, Kume K, Endo F, Katagiri H, Matsuo T, Noda H, Iwaya T, Yamada N, Fujiwara H, Takahashi M, Itabashi T, Uesugi N, Maesawa C, Tamura G, Sugai T, Otsuka K, Koeda K, Wakabayashi G. Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers. PLoS One. 2012;7(8):e43236. doi: 10.1371/journal.pone.0043236. Epub 2012 Aug 14. PMID 22905237